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Abstract
Glycogen storage disease type XIII (GSDXIII) is a very rare inherited metabolic
myopathy characterized by autosomal-recessive mutations in the ENO3 gene
resulting in muscle β-enolase deficiency, an enzymatic defect of the distal part of
glycolysis. Enzyme kinetic studies of two patients presenting with exertion intoler-
ance and recurrent rhabdomyolysis are reported. Next generation sequencing con-
firmed patient 1 was homozygous for p.E187K in ENO3, while patient 2 was
homozygous for p.C357Y. ENO3 variants pathogenicity was confirmed by func-
tional studies in skeletal muscle. p.E187K caused extremely low total enolase
activity. p.C357Y was associated with a higher level of residual activity but kinetic
studies showed a lower maximum work rate (Vmax). This study illustrates that
GSDXIII may be caused by either null mutations leading to β-enolase deficiency
or by mutations that alter the enzyme's kinetic profile. This study highlights the
importance of carrying out functional studies as part of the diagnostic process fol-
lowing the identification of variants with next generation sequencing.
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1 | INTRODUCTION
Glycogen storage disease type XIII (GSDXIII) is a very rare
inherited metabolic myopathy characterized by an enzymatic
defect of the distal part of glycolysis; to date only four patients
have been reported in the literature1,2 The condition is caused
by recessive mutations in ENO3 (OMIM # 131370) resulting
in muscle β-enolase deficiency. Symptoms include exercise
intolerance with myalgia as the predominant symptom and
recurrent rhabdomyolysis (RM). Symptoms are generallyAbbreviations: CK, creatine kinase; GSDXIII, glycogen storage disease
type XIII; P, patient; RM, rhabdomyolysis.
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milder than McArdle disease, the most common glycogen
storage disorder affecting skeletal muscle. Diagnosis of
GSDXIII is by muscle enzymology and molecular genetics.
Here we report the results of enzyme analysis of β-enolase
activity in skeletal muscle tissue from two patients with ENO3
mutations. The individuals reported symptoms of exercise intol-
erance, recurrent RM and normal serum creatine kinase
(CK) levels in between episodes of RM.
2 | METHODS
Patients were identified as carrying ENO3 mutations follow-
ing genetic analysis on a next generation sequencing panel
of genes for acute RM.3
All muscle samples were homogenized (glass: glass
0.1 mm clearance) in ice-cold 0.1 M K2HPO4 pH 8.0 buffer
and centrifuged at 13000 rpm for 3 minutes in a fixed angle
rotor. The supernatant was retained and split in two aliquots,
the first diluted 2-fold with ice-cold 0.1 M K2HPO4 pH 8.0
buffer for protein analysis by the bichronic acid method with
Bovine serum albumin as the standard.4 The second aliquot
was 2-fold diluted with ice-cold 0.1 M K2HPO4 pH 8.0
buffer with 4 mM dithiothertol for enzyme analysis.
Total enolase activity was measured using a linked enzyme
assay monitoring the decrease in fluorescence due to the con-
version of NADH to NAD+. The assay buffer was at pH 7.4
containing Imidazole (125 mM), NADH (750 μM), KCL
(400 mM), and MgSO4 (3 mM). ADP was added as a cofactor
for pyruvate kinase (6 mM). Pyruvate kinase and lactate dehy-
drogenase were added as auxiliary enzymes at final activities of
14.3 U/L, and 27.5 U/L. Reactions were carried out at 30C
and initiated by addition of 2-phosphoglycerate to a final
concentration 3.8 mM.
For analysis of kinetic parameters a control pool of five unaf-
fected skeletal muscle homogenates was prepared by the method
above and both the control pool and patient samples diluted to a
final protein concentration of 0.5 mg/mL. Enzyme activity mea-
surements were made using the above method however the
2-phosphoglycerate concentrations ranged between 0.19 and
3.8 mM. Results were plotted and fitted to the Michaelis Menten
equation usingGraph Pad Prism, Version 7.
3 | RESULTS
3.1 | Case series
Patient one (P1) was previously reported by Masumeci et al,1
and is a 42-year-old Turkish male with consanguineous parents,
who presented with exercise related muscle pain and RM
following sporting activities such as football during childhood
(highest documented serum CK level: 75000 IU/L), but with
normal baseline serum CK (105 IU/L; reference range:
38-204 IU/L). An ischemic forearm exercise test, performed
many years before his diagnosis was inconclusive with a sub-
optimal rise in lactate with no rise in ammonia. Muscle biopsy
was reported as showing normal histology but a mild increase
in glycogen was seen on electron microscopy. Genetic studies
confirmed him to be homozygous for a c.559G>A p.E187K,
resulting in the glutamate residue 187 being replaced with a
lysine (p.E187K). Patient two (P2) is a 23-year-old Asian male
who presented with recurrent RM (highest documented CK:
193000 IU/L). The first RM episode occurred at 14 years of
age. He had normal baseline serum CK (151 IU/L; reference
range: 38-204). Muscle biopsy showed minimal nonspecific
changes. A nonischemic forearm exercise test revealed a maxi-
mum lactate increase of 3.81 mmol/L. Genetic studies con-
firmed that he was homozygous for c.1070G>A mutation in
exon 10 resulting in p.C357Y substation of the cysteine at posi-
tion 357 with a tyrosine. In silico modeling using SIFT, Poly-
Phen2, SNPS 3D, SNPS&GO, PROVEAN predicted the first
mutation pE187K to be deleterious as it is highly conserved res-
idue. Insilco analysis for the C357Y mutation using the same
software was inconclusive and, therefore, assigned as a variant
of unknown significance (VUS).
VUS presents a major diagnostic challenge in the genomic
era. Whole exome panels can lead to findings of multiple
VUS, often the clinician phenotype could be attributed to more
than one VUS. As powerful as the predictive software is for
characterizing VUS, the only accurate way to assign pathoge-
nicity is through functional studies. These can include measure-
ment of substrate accumulation, of similar byproduct build up,
histological staining, or direct measurement of enzyme activity.
Even when in silico model predicts a mutation to be deleterious
if that mutation has not been previously reported (as was the
case with the E187K mutation), it is advised able to confirm
this prediction using functional studies.
3.2 | Biochemical studies
3.2.1 | Muscle enolase activity
Biochemical studies performed on skeletal muscle tissue
showed severely diminished total enolase activity in both
patients (Table 1). The muscle tissue from P2 had higher resid-
ual activity, and the profile of the fluorescence change against
time for the reaction was abnormal when compared with simul-
taneous normal controls (Figure 1). There was a significant lag
in the time for the reaction to initiate: 18 minutes in the affected
tissue compared to 9 minutes in the controls. Following initia-
tion, the rate of reaction was also slower than the controls.
3.2.2 | Kinetic studies
As there was significant residual enzyme activity in patient
two, we decided to investigate further to elucidate if this
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mutation is pathogenic or not by looking at the kinetic char-
acteristic of the enzyme in the muscle homogenate compared
to unaffected samples. The homogenate preparations of mus-
cle tissue from P2 and the pooled normal homogenates had
kinetic profiles that had a good fit with the Michaelis
Menten equation (see Figure 2). The Michaelis parameter
given in Table 2 indicate that the Km for 2-phosphoglycerate
remains unchanged by the p.C357Y mutation, however the
Vmax of the enzyme-catalyzed reaction was half that of the
pooled normal samples.
4 | DISCUSSION
GSDXIII is a rare cause of recurrent RM. Here we report
our findings on a previously confirmed patient as well as a
new patient with recurrent symptoms who was detected by
next generation sequencing. Baseline CK levels in both
patients were normal but much raised during episodes of
RM. Forearm exercise testing revealed a blunt rise in lactate.
Lactate increase was higher in P2. P2 responses were tested
through a nonischemic forearm test, as this has superseded
the use of ischemic forearm exercise testing.5 The identified
mutations were previously unreported, and in both cases
confirmation of diagnosis allowed the clinical team to appro-
priate advice patients on activity to prevent episodes of RM
and improve aerobic capacity.
Biochemical studies on muscle tissue from both patients'
confirmed diminished total enolase activity. Total enolase
activity in P1 was virtually absent (≤10% residual activity)
as previously reported in Musumeci et al.1 Glutamate 187 is
located on the dimer interface in enolase (Figure 3) and
hydrogen bonds with back bone nitrogen of tyrosine 57 of
the other chain. This interaction along with hydrogen bond
formed by the neighboring residue arginine 183 perhaps
stabilizes the dimer:dimer interface. The mutation may dis-
rupt the formation of the hydrogen bonds resulting in the








Control 1 286 421
Control 2 316 364
Control 3 305 345
Control 4 270 424
Control 5 382 655
Patient 1 8 263
Patient 2 98 386
Note: Patient 1 has <3% the activity of the normal controls while patient 2 has
~33% activity of the normal controls. Phosphoglucomutase activity was
measured as a control of sample integrity (normal reference





























FIGURE 1 Reaction profile for total
enolase activity. Expressed as fluorescence
change vs time. Patient 1 (short vertical
lines) shows little activity, patient
2 (circles) shows a slow decrease in
fluorescence with a marked lag in the start
of the reaction compared to the normal
controls
FIGURE 2 Muscle enolase kinetics for patient 2, and a pool of
five normal samples. Data fitted to the Michaelis Menten equation
using Graph Pad Prism, Version 7
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dimer not being formed, and if the monomeric form of eno-
lase is less stable it would be quickly degraded accounting
for the low activity observed.
From the reaction profile and the kinetic parameters
obtained from analysis of the biopsy from P2, it is evident that
the reported mutation did not result in complete loss of enzyme
activity. Instead, the mutation resulted in a slower rate of beta-
enolase activity. Plasma lactate raise assessed by the non-
ischemic forearm exercise test further support the finding of a
functional enzyme in skeletal muscle. We hypothesize that the
mutation alters the active site of the enzyme, by moving
the catalytic residue from its ideal position. While leaving the
three-dimensional confirmation of the residues responsible
for the binding of the 2-phosphogylcerate substrate, intact,
this would account for the lowered Vmax with an unaltered Km
(see Figure 2). One suggestion would be that this 50% decrease
in Vmax would not cause any muscle symptoms during low
energy demand; however when initiating exercise or during
very intense (anaerobic) exercise, there may be inhibition of
the maximal rate of enzyme activity resulting in a “bottle neck”
in the pathway leading to the observed symptoms.
5 | CONCLUSION
Mutations in ENO3 can result in either low total enolase activity
in skeletal muscle tissue (≤10%) or higher residual activity but
with an altered kinetic parameter of the enzyme resulting in
either reduced availability or working capacity of the enzyme
for substrate metabolism. This study illustrates the importance
of using functional studies to confirm novel mutations identified
on next generation sequencing panels. As with all diagnostic
tools, functional studies should be used to answer the clinical
question as best as possible. This is likely to be as part of a mul-
tidisciplinary team approach in complex cases such as theses.
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FIGURE 3 Homodimer of enolase, one dimer shown as a cyan
ribbon, second dimer colored showing secondary structure, residue
Glu187 shown in purple. Magnesium ions shown as grey spheres with
2-phosphoglycerate represented as yellow sticks. The side changes of
substrate binding residues His 156, Glu 167, Glu 210, Lys 394 shown
as blue sticks, catalytic residue side chain Lys 343 represented by
orange sticks. Cystine 357 has been mutated to tyrosine the side chain
resented by pink sticks. Image generated using the PyMOL Molecular
Graphics System, Version 1.3 Schrödinger, LLC, PDB code 3UCC
TABLE 2 Kinetic parameters of patient 2 and pool of five normal
controls
Sample Km (μmol/L) Vmax (μmol/min/mg ptn)
Pool of normal
controls (N = 5)
0.92 4113
C357Y 0.94 2445
Note: Km in patient 2 is comparable to normal controls, meaning there is no
change in the affinity of the total enolase in patient 2 for 2-phosphoglycerate.
The Vmax in patient 2, however is ~50% that of the normal controls.
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